PB Fintech slides 42.9% in four sessions as proposed IRDAI commission caps unsettle investors
PB Fintech shares fell 42.9 per cent to ₹1,077, a 52-week low amid proposed IRDAI commission reforms. Health-insurance caps are 15 per cent for new policies and 5 per cent for renewals. Elara cut its target to ₹1,400 from ₹1,990, while retaining its buy rating.
Read the source at The Hindu BusinessLineNewer on PB Fintech · — may update this storyPB Fintech shares fall 48% in six sessions amid proposed Irdai reforms
Why it matters to operators and investors
Proposed IRDAI caps on health-insurance commissions could pressure distribution economics, so reassess new-policy and renewal margins.
What to watch next
- IRDAI consultation responses, final wording, effective date, and any transition or grandfathering provisions
- Whether the caps apply uniformly across products, distribution channels, and policy types
- PB Fintech commentary on health insurance exposure, renewal economics, and commission revenue
- Quarterly trends in insurance premium growth, contribution margins, customer-acquisition costs, and renewal retention
- Insurer moves toward direct distribution, revised broker terms, or changes to premiums and product benefits
The counter-case
The 42.9% fall is dramatic, but the signal overstates what is known: the commission caps are proposed, not necessarily final, and the price move alone does not establish that they will materially impair PB Fintech’s earnings. The retained buy rating and ₹1,400 target also suggest at least one broker sees substantial recovery potential.